Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for HEPZATO™ in Metastatic colorectal cancer. The expected timing is based on the latest available company guidance and may change.
12/2/24- FDA cleared IND for Ph2 trial. Begin patient enrollment in H2 2025. 8/20/25- First patient dosed in Ph2 trial. Primary endpoint data in Mid-2028; secondary endpoint & OS data in Late 2028 11/06/25:- Global Ph2 mCRC trial enrolling ~90 patients at 20+ sites; first patient dosed August 2025; topline data in 2028. 02/26/26:- 2025 R&D increase partly due to ongoing Ph2 HEPZATO trial in mCRC and mBC. 05/07/26:- Phase 2 HEPZATO colorectal trial ongoing; Q1 2026 R&D spending increased supporting trial operations. 08/06/26:- HEPZATO colorectal development continued; Ph2 data expected Mid-2028.
Verification
Confirm timing and program details against the company announcement or filing.